Study Stopped
Insufficient funds
Connecting Periodontal and Coronary Artery Disease Via the Inflammatory State of the Body
1 other identifier
observational
N/A
0 countries
N/A
Brief Summary
Cardiovascular disease is one of the leading causes of death in the United States and the world. Many interventions relating to prevention have been emphasized as more risk factors for this devastating disease are discovered. Periodontal disease is known to have a close association with cardiovascular disease, but its role as a risk factor is still not well understood. Inflammation is a driving force in both of these diseases, creating a potential bridge between the two. Specifically, periodontal disease can cause an inflammatory reaction in the body, which may predispose or even directly contribute to atheroma formation in the coronary arteries. In this study, the investigators will study the link between the inflammatory state of the body and will search for a correlation with levels of coronary artery disease and periodontal disease. Inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), and immunoglobulin G (IgG) levels in the patient's blood will be analyzed and correlated to clinical attachment loss measured via pocket depth measurement, the distance from the gingival margin to the base of the pocket. A definitive link between these disease processes will allow preventive measures to be taken earlier to prevent this lifelong disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Oct 2016
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 18, 2016
CompletedFirst Submitted
Initial submission to the registry
January 26, 2017
CompletedFirst Posted
Study publicly available on registry
February 3, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 13, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 13, 2017
CompletedJanuary 30, 2020
January 1, 2020
9 months
January 26, 2017
January 28, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Level of periodontal disease
one day
Secondary Outcomes (4)
ESR
one day
Myeloperoxidase (MPO)
one day
IgG
one day
hs-CRP
one day
Study Arms (3)
No Coronary Artery Disease (CAD)
Patients with no known cardiovascular disease.
CAD without Myocardial Infarction (MI)
Patients with cardiovascular disease without a myocardial infarction.
CAD with MI
Patients with cardiovascular disease with previous history of a myocardial infarction.
Interventions
A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects
Eligibility Criteria
All patients from ages 18-89 years who are being seen in the Center for Cardiovascular Health at TTUHSC and at Dr. Johnson's dental clinic who meet the inclusion criteria, and who will consent to participating in the study. There will be between 25 to 35 patients in each group.
You may qualify if:
- Patients with known CAD with previous MI, OR
- Patients without known CAD
- Ages 18-89 years
- Patients who have dental implants with a recorded patient history of how the teeth were lost
- Patients with at least one tooth in each of the four quadrants of the mouth
- Able to obtain all necessary pocket measurements and blood samples needed for the study
You may not qualify if:
- Patients with a known history of rheumatoid arthritis
- Patients with a known history of lupus
- Patients currently under the care of a rheumatologist
- Patients who have had a MI in the two weeks prior to entering the study
- Patients with a previous history of coronary artery bypass graft
- Current smokers and tobacco users
- Patients on disease-modifying agents for rheumatoid arthritis (methotrexate)10. Patients who have undergone chemotherapy in the past five years
- Patients who currently use steroids or immunosuppressive agents
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Ami Knox, MBA
Texas Tech University Health Sciences Center
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 26, 2017
First Posted
February 3, 2017
Study Start
October 18, 2016
Primary Completion
July 13, 2017
Study Completion
July 13, 2017
Last Updated
January 30, 2020
Record last verified: 2020-01
Data Sharing
- IPD Sharing
- Will not share
Data will not be shared with other researchers